In this single-centre, post-approval setting, we report data of 51 patients with different stages of lung disease, age 2–52 years with repeated measurements of forced expiratory volume as a percentage of the predicted value (ppFEV1) and LCI after 2, 4, and 16 weeks of CFTR modulator treatment and at baseline. Here, CFTR is linked to lung disorder.